Ads
related to: drugs that increase gi motility in men and prostate cancer patients live- Case Studies
Review real case studies
with real patients.
- Sign Up for Updates
Sign up to receive the latest data,
case studies, and resources.
- Find an Imaging Site
Locate the nearest imaging site
or contact customer service.
- Contact Us
Contact our representatives
for product and reimbursement info.
- Case Studies
Search results
Results from the WOW.Com Content Network
Activation of a wide range of serotonin receptors by serotonin itself or by certain prokinetic drugs results in enhanced gastrointestinal motility. [3] Other prokinetic drugs may increase acetylcholine concentrations by stimulating the M 1 receptor which causes acetylcholine release, or by inhibiting the enzyme acetylcholinesterase which ...
The muscarinic receptors in the bladder and gastrointestinal tract stimulate contraction of the bladder and expulsion of urine, and increased gastrointestinal motility, respectively. Bethanechol should be used to treat these disorders only after mechanical obstruction is ruled out as a possible cause.
For premium support please call: 800-290-4726 more ways to reach us
The American Urological Association advises that increased risk for patients taking these drugs leads to higher prostate cancer-specific and all-cause mortality. [30] The AUA also advises that this affect can be alleviated with more frequent screening and lower PSA cutoffs for diagnostic biopsies in men taking dutasteride or other 5α-reductase ...
A new method to reduce rectal radiation injury in prostate cancer patients involves the use of an absorbable spacer placed between the prostate and rectum. MRI showing hydrogel spacer pushing the rectum away from the prostate during radiotherapy. Such spacers are commercially available in some regions and are undergoing clinical trials in ...
Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...
Ads
related to: drugs that increase gi motility in men and prostate cancer patients live